Periodic Reporting for period 1 - Balanseat Phase-1 (THE ONLY WALKING REHABILITATION DEVICE THAT FITS THE CAPABILITIES OF THE FRAIL ELDERLY & NEUROLOGICAL IMPAIRED)
Berichtszeitraum: 2018-12-01 bis 2019-05-31
MoPair Technologies is developing a solution for reducing risk of falls and improving ambulation in old elderly population. Falls, which mostly occur while walking, are the leading cause of fatal and non-fatal injuries in elderly population. Falls threaten seniors’ safety and independence and generate enormous economic and personal costs.
Furthermore, social isolation in home-bound elderly’s has major impact on wellbeing and life quality thus improved ambulation may allow home-bound elderly’s to return to community activities. Clinical case series done at an assisted living facility and published last year demonstrated marked improvements in common physiotherapy functional parameters that are correlated to risk of falls and users' ambulation.
Furthermore, social isolation in home-bound elderly’s has major impact on wellbeing and life quality thus improved ambulation may allow home-bound elderly’s to return to community activities. Clinical case series done at an assisted living facility and published last year demonstrated marked improvements in common physiotherapy functional parameters that are correlated to risk of falls and users' ambulation.
During the term of this phase 1 grant the company focused on the following areas:
1. initiate pilots in its first European addressable market
Since program start MoPair initiated product pilots in three leading elderly chains in the Netherlands. Product evaluations are currently in progress. Company was able to get variety of product and clinical related inputs from these organizations.
2. Initiate a formal clinical study with partner
In two of the above chains, MoPair is planning to conduct a formal clinical study lead by a known principal investigator from a leading university in Holland. A leading multinational corporation may join the study at a second phase with its add-on solution.
3. Explore main European market characteristics and reimbursement
Company decided to focus on 3 leading countries: Germany, UK and France. During the term of the grant valuable market and reimbursement info was gathered.
4. Survey for product enhancements
During the term of phase 1, we focused on defining major new features to the institutional product and initial design of our upcoming home product.
1. initiate pilots in its first European addressable market
Since program start MoPair initiated product pilots in three leading elderly chains in the Netherlands. Product evaluations are currently in progress. Company was able to get variety of product and clinical related inputs from these organizations.
2. Initiate a formal clinical study with partner
In two of the above chains, MoPair is planning to conduct a formal clinical study lead by a known principal investigator from a leading university in Holland. A leading multinational corporation may join the study at a second phase with its add-on solution.
3. Explore main European market characteristics and reimbursement
Company decided to focus on 3 leading countries: Germany, UK and France. During the term of the grant valuable market and reimbursement info was gathered.
4. Survey for product enhancements
During the term of phase 1, we focused on defining major new features to the institutional product and initial design of our upcoming home product.
As part this phase 1 grant, we improved our understanding of the European market conditions and the associated risks that need to be considered as the company develops a detailed business plan for rolling out, and scaling up Balanseat as a marketable innovative solution.